Phase 3 Randomized Study With ONC-392 vs. Docetaxel in PD-1 Resistant NSCLC
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen
anti-CTLA-4 antibody, ONC-392, in patients with metastatic non-small cell lung cancer who
have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test
whether ONC-392, in comparison with chemotherapy agent Docetaxel, could prolong the life for
NSCLC patients. Patients will be randomized to be treated with either ONC-392 or Docetaxel,
IV infusion, once every 21 days, for up to 17 cycles in approximately one year.